MedTrace Logo

Effect of Treatment With Insulin VIAjectTM Compared to Regular Human Insulin and Insulin Lispro on Mealtime Blood Vessel Stress in Patients With Type 2 Diabetes Mellitus.

NCT00849576 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2015-08-03

No results posted yet for this study

Summary

The purpose of this study is to compare the effects of insulin VIAject with Regular Human Insulin and Insulin Lispro on measures of mealtime blood vessel stress and blood flow.

Conditions

Interventions

DRUG

Regular Human Insulin

0.10 U/Kg- 15 minutes before ingestion of a standardized liquid meal.

DRUG

Insulin Lispro

90% of Regular Human Insulin dose administer immediately before ingestion of a standardized liquid meal.

DRUG

Insulin VIAject™ (75%)

75 % of Regular Human Insulin dose administer immediately before ingestion of a standardized liquid meal

DRUG

Insulin VIAject™ (90%)

90 % of Regular Human Insulin dose administer immediately before ingestion of a standardized liquid meal

Sponsors & Collaborators

  • Biodel

    lead INDUSTRY

Principal Investigators

  • Thomas Forst, MD · IKFE Institute for Clinical Research and Development

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2008-08-31
Completion
2008-08-31

Countries

  • Germany

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00849576 on ClinicalTrials.gov